Testing surgery plus immunotherapy for metastatic kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies whether removing the kidney tumor (cytoreductive nephrectomy) before treatment can improve outcomes for people with metastatic clear-cell kidney cancer. All participants are expected to receive standard immunotherapy (nivolumab plus ipilimumab), and the study focuses on the role of surgery in the “immuno-oncology era.”
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your metastatic kidney cancer must be biopsy-proven clear-cell type only
- Your kidney cancer must still be present in the kidney at the time of enrollment
- You must be able and willing to follow the study plan and visits
- You must have measurable cancer on scans and an expected survival of more than 4 months
- You must have not had any prior whole-body (systemic) treatment for metastatic kidney cancer
- Your blood, liver, and kidney tests must meet study safety thresholds
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether removing the kidney tumor with “deferred cytoreductive nephrectomy” (surgery at a later time) works best for people whose metastatic kidney cancer is already present. It compares a standard treatment approach using either immunotherapy (nivolumab/ipilimumab) or a targeted pill plus immunotherapy (TKI/IO), with planned surgery afterward.
This trial is for people with kidney cancer that has spread to other parts of the body, who still have their original kidney tumor. If your cancer has responded very well to immunotherapy (a type of treatment that helps your immune system fight cancer), doctors want to see if removing the kidney tumor now can improve your outcome.
This trial tests whether removing or burning (ablating) the main kidney tumor helps people with advanced kidney cancer who are already doing well on immunotherapy. Researchers want to see if combining local treatment with ongoing immunotherapy can improve outcomes.
This trial tests a new oral drug (HC-7366) combined with two immunotherapy drugs (nivolumab and ipilimumab) for people with advanced clear cell kidney cancer. The goal is to see if adding this new drug can help shrink tumors or slow the cancer's growth.
This study tests whether adding surgery to remove the kidney improves outcomes compared with continuing immunotherapy without surgery. It is for people with metastatic kidney cancer whose disease has not worsened after initial immunotherapy.
This study looks at whether people with metastatic kidney cancer can be managed with standard immune-based treatment and then have their main kidney tumor removed. It is meant for people who can have surgery and whose cancer has not grown at the time this approach is considered.
Hear when a new Kidney Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.